bioRxivBiophysicsPreprint
Stretched Exponential Modeling Reveals Drug-Specific Kinetics in Human Engineered Skeletal Muscle
Mattias LuberiD, Bruno Schmelz, Christof LenziD, Timo BetziD
Abstract
Understanding muscle tissue is key not only for advancing our knowledge in biophysical function of the human body, but can also open new paths to better description of pathological states, improve treatment and training and even provide insights for drug development. While using excised muscles is an excellent way to study muscular function, this limits access to non-human tissue, as human muscle tissue donation is very limited. The past decade has seen a rise in 3D in vitro models of human skeletal muscle, however many current experimental approaches to create such models often struggle with the high variability of primary cells or the limited translational relevance in cases where murine lines are used. Furthermore, the state-of-the-art functional analysis is typically focusing at peak force, which overlooks critical kinetic information. In this study, we present an systematic approach to generate functional engineered skeletal muscle tissues (ESMs), measure the contraction force dynamics and model these with a new approach to extract the effect of a series of standard pharmacological modulators. Within 14 days, LHCN-M2 ESMs mature into aligned, multinucleated myofibers expressing key sarcomeric markers and exhibiting robust excitation-contraction coupling. To decode these dynamics, we introduce a novel mathematical model based on stretched exponential functions. This framework accurately captures the heterogeneous contraction and relaxation phases across diverse phenotypes using only six interpretable parameters. We validated the platforms sensitivity using a library of pharmacological modulators. Our kinetic modeling revealed a distinct parameter fingerprint for different drug classes such as the specific changes of contraction kinetics that peak force alone could not detect. Additionally the presence of the necessary drug targets as well as the state of maturation were investigated by proteomic profiling. Together, study provides a scalable, high-fidelity human platform for high-content pharmacological screening and muscle biophysics.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel ex vivo model of nerve-induced skeletal muscle contraction
Carole Dabadie, Elise Belaïdi, … Rémi Mounier·bioRxiv·Oct 10, 2024
- 3D-printed drug testing platform based on a 3D model of aged human skeletal muscle
R. Mestre, N. Garcia, … S. Sanchez·bioRxiv·Jun 18, 2020
- A 96-well culture platform enables longitudinal analyses of engineered human skeletal muscle microtissue strength
M. E. Afshar, H. Y. Abraha, … P. M. Gilbert·bioRxiv·Feb 28, 2019
- Bioengineering a Miniaturized In Vitro 3D Myotube Contraction Monitoring Chip For Modelization of Muscular Dystrophies
N. Rose, S. Sonam, … L. Trichet·bioRxiv·Jun 15, 2021
- High-throughput, real-time monitoring of engineered skeletal muscle function using magnetic sensing
A. S. T. Smith, S. M. Luttrell, … D. L. Mack·bioRxiv·May 20, 2022
- On the rate-limiting dynamics of force development in muscle
Tim J. van der Zee, Jeremy D. Wong, Arthur D. Kuo·Journal of Experimental BiologyPeer-reviewed·Sep 12, 2024